<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7551260\results\search\zoonosis\results.xml">
  <result pre="severe acute respiratory symptom (SARS) outbreak in 2002âˆ’2003 [1], and" exact="Middle East respiratory syndrome" post="coronavirus (MERS), which emerged in 2012 [2]. At the"/>
  <result pre="Betacoronaviruses, which mainly include severe acute respiratory symptoms coronavirus (SARS-CoV)," exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV), severe acute respiratory symptoms coronavirus 2 (SARS-CoV-2),"/>
  <result pre="activate the S protein for membrane fusion in SARS-CoV and" exact="SARS-CoV-2 infection" post="[30]. Notably, ACE2 and TMPRSS2 are also highly expressed"/>
  <result pre="suggested that the digestive system is a potential route for" exact="SARS-CoV-2 infection" post="[33,34]. 3. Antiviral Immune Responses to Coronavirus Infection The"/>
  <result pre="molecules induces an effective host cell-intrinsic antiviral defense against lethal" exact="SARS-CoV infection" post="[50]. In contrast, TLRs 7 and 8 of plasmacytoid"/>
  <result pre="which effectively reduces the severity of MHV-induced pathogenesis [58]. Nevertheless," exact="SARS-CoV infection" post="causes temporal and spatial activation of the transcriptional factor"/>
  <result pre="been recommended as potential therapeutic drugs to prevent and treat" exact="SARS-CoV-2 infection" post="[70,71,72]. Notably, excessive and prolonged IFN expression might lead"/>
  <result pre="use in clinical practice against viral infection. 3.3.2. Proinflammatory Cytokines" exact="SARS-CoV infection" post="induces upregulation of proinflammatory cytokines/chemokines, such as interleukin (IL)-1Î²,"/>
  <result pre="changes in the proinflammatory response at the early stage of" exact="SARS-CoV-2 infection." post="In this context, Ong et al. conducted daily transcriptional"/>
  <result pre="disease severity [81]. The potential ISGs exert protective functions against" exact="SARS-CoV-2 infection," post="which may explain the lower proportion of severe cases"/>
  <result pre="load has been detected at the very early phase of" exact="SARS-CoV-2 infection" post="after symptom onset [83], suggesting that the novel emerging"/>
  <result pre="is available about the roles of DCs and pDCs in" exact="SARS-CoV-2 infection." post="Thus, further investigation is required to elucidate whether the"/>
  <result pre="replication may be particularly active during the early phrase of" exact="SARS-CoV-2 infection;" post="thus, antiviral therapy could exerts its greatest effects before"/>
  <result pre="are used as therapy for dysregulated innate immune responses to" exact="SARS-CoV-2 infection." post="Currently recommended agents include corticosteroids, interleukin inhibitors, IFNs, and"/>
  <result pre="[127]. A summary of the action of these agents against" exact="SARS-CoV-2 infection" post="is shown in Table 1. Besides the pharmacologic interventions,"/>
  <result pre="the recognition of SARS-CoV-2 by full-length human ACE2Science20203671444144810.1126/science.abb276232132184 26.TeN.Vergara-AlertJ.LehmbeckerA.PerezM.HaagmansB.L.BaumgartnerW.BensaidA.SegalesJ.Co-localization of" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) and dipeptidyl peptidase-4 in the respiratory tract"/>
  <result pre="Immunol.2017101581159310.1038/mi.2017.1628327617 41.LiW.HulswitR.J.G.WidjajaI.RajV.S.McBrideR.PengW.WidagdoW.TortoriciM.A.van DierenB.LangY.et al.Identification of sialic acid-binding function for the" exact="Middle East respiratory syndrome" post="coronavirus spike glycoproteinProc. Natl. Acad. Sci. USA2017114E8508E851710.1073/pnas.171259211428923942 42.JungK.SaifL.J.Goblet cell"/>
  <result pre="on Toll-like receptorsNat. Immunol.20101137338410.1038/ni.186320404851 47.NazA.ShahidF.ButtT.T.AwanF.M.AliA.MalikA.Designing multi-epitope vaccines to combat emerging" exact="coronavirus disease 2019" post="(COVID-19) by employing immuno-informatics approachFront. Immunol.202011166310.3389/fimmu.2020.0166332754160 48.MarchantD.SingheraG.K.UtokaparchS.HackettT.L.BoydJ.H.LuoZ.S.SiX.N.DorscheidD.R.McManusB.M.HegeleR.G.Toll-like receptor 4-mediated"/>
  <result pre="severe COVID-19Nat. Med.2020261070107610.1038/s41591-020-0944-y32514174 82.WuZ.McGooganJ.M.Characteristics of and important lessons from the" exact="coronavirus disease 2019" post="(COVID-19) outbreak in China: Summary of a report of"/>
  <result pre="4, and 6 induce double-membrane vesiclesmBio20134e00524-1310.1128/mBio.00524-1323943763 92.OudshoornD.RijsK.LimpensR.GroenK.KosterA.J.SnijderE.J.KikkertM.BarcenaM.Expression and cleavage of" exact="Middle East respiratory syndrome" post="coronavirus nsp3-4 polyprotein induce the formation of double-membrane vesicles"/>
  <result pre="protease?J. Virol.2005794550455110.1128/JVI.79.7.4550-4551.200515767458 104.YangX.ChenX.BianG.TuJ.XingY.WangY.ChenZ.Proteolytic processing, deubiquitinase and interferon antagonist activities of" exact="Middle East respiratory syndrome" post="coronavirus papain-like proteaseJ. Gen. Virol.20149561462610.1099/vir.0.059014-024362959 105.XingY.ChenJ.TuJ.ZhangB.ChenX.ShiH.BakerS.C.FengL.ChenZ.The papain-like protease of"/>
  <result pre="HealthAvailable online: https://www.covid19treatmentguidelines.nih.gov(accessed on 27 August 2020) 124.SandersJ.M.MonogueM.L.JodlowskiT.Z.CutrellJ.B.Pharmacologic treatments for" exact="coronavirus disease 2019" post="(COVID-19): A reviewJAMA202010.1001/jama.2020.601932282022 125.AoubaA.BaldolliA.GeffrayL.VerdonR.BergotE.Martin-SilvaN.JustetA.Targeting the inflammatory cascade with anakinra"/>
  <result pre="a less toxic derivative of chloroquine, is effective in inhibiting" exact="SARS-CoV-2 infection" post="in vitroCell Discov.2020610.1038/s41421-020-0156-0 134.SchoergenhoferC.JilmaB.StimpflT.KarolyiM.ZoufalyA.Pharmacokinetics of lopinavir and ritonavir in"/>
  <result pre="Discov.2020610.1038/s41421-020-0156-0 134.SchoergenhoferC.JilmaB.StimpflT.KarolyiM.ZoufalyA.Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with" exact="coronavirus disease 2019" post="(COVID-19)Ann. Intern. Med.2020M20-155010.7326/M20-1550 135.GroupR.C.HorbyP.LimW.S.EmbersonJ.R.MafhamM.BellJ.L.LinsellL.StaplinN.BrightlingC.UstianowskiA.et al.Dexamethasone in hospitalized patients with"/>
  <result pre="leukocyte subpopulationsArthritis Res. Ther.20192118310.1186/s13075-019-1964-131375130 139.CaoY.WeiJ.ZouL.JiangT.WangG.ChenL.HuangL.MengF.HuangL.WangN.et al.Ruxolitinib in treatment of severe" exact="coronavirus disease 2019" post="(COVID-19): A multicenter, single-blind, randomized controlled trialJ. Allergy Clin."/>
  <result pre="red boxes. S, severe acute respiratory symptom coronavirus (SARS-CoV); M," exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV); P, porcine epidemic diarrhea virus (PEDV); PD,"/>
 </snippets>
</snippetsTree>
